Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ILOPERIDONE vs ABILIFY MAINTENA KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iloperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors; also moderate affinity for D3, D4, 5-HT6, 5-HT7, and α1-adrenergic receptors; low affinity for H1, 5-HT1A, and α2-adrenergic receptors; no affinity for M1 muscarinic receptors.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Acute treatment of schizophrenia in adults
Treatment of schizophrenia,Maintenance monotherapy for bipolar I disorder,Adjunctive treatment of major depressive disorder (off-label),Irritability associated with autistic disorder (off-label),Tourette's disorder (off-label)
1-2 mg orally twice daily; target dose 6-12 mg/day; maximum 12 mg/day
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
Terminal elimination half-life 18 hours in extensive CYP2D6 metabolizers, 33 hours in poor metabolizers; clinical context: steady-state reached in ~5-7 days.
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Primarily metabolized by CYP3A4 and CYP2D6 to two major metabolites (P88 and P95); also a minor substrate of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2E1.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole.
Primarily hepatic metabolism via CYP3A4 and CYP2D6; approximately 7% excreted unchanged in urine and 18% in feces; total renal elimination of metabolites ~25%, fecal ~60%.
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
~95% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
Aripiprazole is >99% bound to serum albumin and alpha-1-acid glycoprotein.
Vd/F ~20 L/kg (oral); large distribution indicates extensive tissue binding.
Aripiprazole: 4.9 L/kg (range 3.7-7.2 L/kg), indicating extensive tissue distribution.
Oral bioavailability is approximately 96% relative to oral solution; food does not significantly affect absorption.
IM (Abilify Maintena): 100% relative to oral aripiprazole after 5 monthly doses; oral: 87%.
GFR 30-59 m L/min: reduce dose by 50%; GFR 15-29 m L/min: reduce by 75%; GFR <15 m L/min: not recommended
No adjustment for mild/moderate impairment; caution in severe impairment (Cr Cl <30 m L/min).
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: contraindicated
No adjustment for mild impairment; moderate to severe (Child-Pugh class B or C): reduce dose to 300 mg/month.
Not established; safety and efficacy not evaluated in patients <18 years
Not approved for pediatric use.
Initiate at 1 mg twice daily; increase slowly; monitor for orthostatic hypotension and anticholinergic effects
Use cautiously due to increased sensitivity; consider lower doses and monitor for adverse effects.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Iloperidone is not approved for the treatment of patients with dementia-related psychosis.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Increased mortality in elderly patients with dementia-related psychosis,QT interval prolongation (particularly with concomitant use of drugs that prolong QT or in patients with risk factors),Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Metabolic changes (hyperglycemia, dyslipidemia, weight gain),Orthostatic hypotension (particularly during initial dose titration),Seizures,Leukopenia, neutropenia, and agranulocytosis,Body temperature regulation impairment,Dysphagia,Cognitive and motor impairment
Increased mortality in elderly dementia patients; suicidal thoughts and behaviors; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); orthostatic hypotension; leukopenia/neutropenia; seizure risk; dysphagia; body temperature dysregulation; pathological gambling and other impulse control disorders.
Known hypersensitivity to iloperidone or any component of the formulation
Hypersensitivity to aripiprazole or any excipients in the formulation.
Grapefruit juice may inhibit CYP3A4 metabolism, increasing iloperidone concentrations; avoid concurrent use. High-fat meals may slightly reduce absorption; take consistency.
No specific food interactions. Grapefruit/grapefruit juice may increase aripiprazole levels (CYP3A4 inhibition). Avoid excessive alcohol consumption.
First trimester: Limited human data; animal studies show increased fetal resorption and developmental delays at doses similar to human exposure. Second and third trimesters: May cause extrapyramidal symptoms and/or withdrawal symptoms in neonates (e.g., agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, including aripiprazole, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms post-delivery.
Iloperidone is excreted into human milk. M/P ratio: unknown. Use caution; consider benefits of breastfeeding vs. risk of infant exposure. Monitor infant for sedation, poor feeding, extrapyramidal symptoms.
Aripiprazole is excreted in human breast milk; the estimated infant dose is 0.7–1.4% of maternal weight-adjusted dose. M/P ratio: approximately 0.3–0.5. Limited data suggest no adverse effects in breastfed infants, but long-term safety is unknown.
No specific dose adjustment guidelines exist for pregnancy. Due to increased plasma volume and renal clearance during pregnancy, consider therapeutic drug monitoring to maintain efficacy. Lower doses may be needed if adverse effects occur; use lowest effective dose.
No specific dose adjustment recommended based on pharmacokinetic changes; however, therapeutic drug monitoring may be considered due to altered metabolism in pregnancy. The long-acting injectable formulation (Abilify Maintena) requires careful timing of doses postpartum to avoid relapse.
Iloperidone is an atypical antipsychotic with a low propensity for extrapyramidal symptoms but significant QTc prolongation risk; obtain baseline ECG and monitor electrolytes. Titrate slowly to mitigate orthostatic hypotension due to alpha-1 blockade. Dosing adjustments required in CYP2D6 poor metabolizers (reduce dose by 50%). Avoid concomitant use with QT-prolonging drugs or CYP3A4/2D6 inhibitors/inducers.
Administer every 4 weeks by intramuscular injection only. Do not substitute for oral aripiprazole on a mg-per-mg basis due to different pharmacokinetics. Requires initiation and continuation with oral aripiprazole for 14 days to establish tolerability. Monitor for neuroleptic malignant syndrome, tardive dyskinesia, and metabolic changes. Dose adjustments needed in patients with known CYP2D6 poor metabolizer status or concurrent use of strong CYP2D6 or CYP3A4 inhibitors.
Do not drive or operate machinery until you know how iloperidone affects you, as it may cause dizziness, drowsiness, or blurred vision.,Rise slowly from sitting or lying positions to prevent falls due to low blood pressure.,Report any fast, pounding, or irregular heartbeat, especially with lightheadedness or fainting.,Avoid alcohol and grapefruit juice as they may increase side effects or drug levels.,If you experience muscle stiffness, fever, confusion, or sweating, seek emergency help immediately, as these may be signs of neuroleptic malignant syndrome.
This medication is given as an injection every 4 weeks by a healthcare professional.,Do not stop taking your oral aripiprazole until your doctor tells you to.,Seek emergency care if you experience fever, muscle stiffness, confusion, or irregular heartbeat.,Avoid alcohol and driving until you know how this medicine affects you.,Report any uncontrolled movements of the face, tongue, or other body parts to your doctor.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
"Iloperidone, an atypical antipsychotic, prolongs the QT interval by blocking cardiac potassium channels (hERG), while Methsuximide, a succinimide anticonvulsant, may also prolong the QT interval via similar mechanisms. Co-administration can lead to additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias. This is particularly dangerous in patients with electrolyte imbalances, bradycardia, or pre-existing cardiac disease."
"The interaction between iloperidone and aprepitant results from iloperidone's moderate inhibition of CYP3A4, the primary enzyme responsible for aprepitant metabolism. This inhibition can lead to increased aprepitant plasma concentrations, potentially enhancing its antiemetic effects and risk of adverse events such as hiccups, constipation, and headache. Clinical significance is greater during the 3-day aprepitant regimen for chemotherapy-induced nausea and vomiting, as elevated levels may prolong its therapeutic and side effect profile."
"Concomitant administration of propoxycaine, an ester-type local anesthetic, and iloperidone, an atypical antipsychotic, may increase the risk of QT interval prolongation and torsade de pointes due to additive effects on cardiac repolarization. Propoxycaine can also elevate catecholamine levels, potentially enhancing iloperidone's effects on blood pressure and heart rate. These interactions could manifest as palpitations, syncope, or life-threatening arrhythmias."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ILOPERIDONE vs ABILIFY MAINTENA KIT, answered by our medical review team.
ILOPERIDONE is a Atypical Antipsychotic that works by Iloperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors; also moderate affinity for D3, D4, 5-HT6, 5-HT7, and α1-adrenergic receptors; low affinity for H1, 5-HT1A, and α2-adrenergic receptors; no affinity for M1 muscarinic receptors.. ABILIFY MAINTENA KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ILOPERIDONE and ABILIFY MAINTENA KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ILOPERIDONE is: 1-2 mg orally twice daily; target dose 6-12 mg/day; maximum 12 mg/day. The standard adult dose of ABILIFY MAINTENA KIT is: 400 mg IM once monthly after establishing tolerability with oral aripiprazole.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ILOPERIDONE and ABILIFY MAINTENA KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ILOPERIDONE is classified as Category A/B. First trimester: Limited human data; animal studies show increased fetal resorption and developmental delays at doses similar to human exposure. Second and third trimesters: May ca. ABILIFY MAINTENA KIT is classified as Category C. First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, includin. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.